 
 
	Healthcare systems are facing a huge rise in demand for emergency room visits, ward admissions and ICU entries. Despite medical departments reforms and clinical appointments rescheduling, critical status patients with life-threatening severe aortic stenosis and other conditions are being postponed.
	This situation poses unique challenges to the care of non-COVID patients and interventional community is worried. A concerted strategy to mitigate the effects of COVID-19 in structural heart disease (SHD) must be in place.
	
	We face short- and long-term unpredictable consequences, so we must plan ahead the way we are dealing with this challenge and how are we going to resume interventional cardiology procedures, specially TAVI.
	 
| 
					17:30 | 
					Regional situation of the cardiovascular impact of COVID-19 pandemic in Europe: overview Panel roundtable | 
| 18:00 | 
					At the crossroads of COVID-19 and interventional cardiology 
					Ignacio Cruz Gonzalez 
					Q&A Session | 
| 18:25 | 
						Management and monitoring of Mitral regurgitation and other SHD patients: distinctions of patients at risk and practical recommendations 
						Giuseppe Tarantini 
						Q&A Session | 
| 18:50 | 
					Management and monitoring of Aortic Stenosis patients: distinctions of patients at risk and practical recommendations 
					Nicolas Van Mieghem Q&A Session | 
| 19:30 | 
					Conclusion | 
Supported by an unrestricted educational grant
	